What is the growth forecast for the Cell-free DNA Mutation Diagnostics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Cell-free DNA Mutation Diagnostics market?

Key drivers include advances in technology, rising cancer incidence, and growing demand for non-invasive diagnostics.

What are the major challenges facing the Cell-free DNA Mutation Diagnostics market?

Challenges include high costs, regulatory hurdles, and limited reimbursement for cell-free DNA tests.

Which regions are leading the Cell-free DNA Mutation Diagnostics market?

North America and Europe are regional leaders, driven by strong healthcare infrastructure and research initiatives.

Who are the top companies in the Cell-free DNA Mutation Diagnostics market?

Top companies include Illumina, Roche, and Thermo Fisher, offering a range of diagnostic solutions and services.

What future opportunities exist in the Cell-free DNA Mutation Diagnostics market?

Future opportunities include expanding into new applications, such as prenatal testing and infectious disease diagnosis.

How is technology impacting the Cell-free DNA Mutation Diagnostics market?

Advances in next-generation sequencing and artificial intelligence are enhancing diagnostic accuracy and efficiency.

What is the current regulatory landscape for the Cell-free DNA Mutation Diagnostics market?

The regulatory landscape is evolving, with ongoing efforts to establish clear guidelines and standards for cell-free DNA testing.

What is the future outlook for the Cell-free DNA Mutation Diagnostics market?

The future outlook is promising, with growing demand and ongoing innovation expected to drive market growth and expansion.

Cell-free DNA Mutation Diagnostics Expansion Opportunities & Forecast Analysis 2033

Cell-free DNA Mutation Diagnostics by Application (Hoispital, Clinic, Laboratories, Others), by Types (Kits, Instruments, Services), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $8130 million

CAGR: 15%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $8130 million

CAGR: 15%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cell-free DNA Mutation Diagnostics Market Overview

The Cell-free DNA Mutation Diagnostics market refers to the industry focused on developing and commercializing diagnostic tests that detect genetic mutations in cell-free DNA. As the Cell-free DNA Mutation Diagnostics market size is expected to grow significantly, driven by its growth outlook and market forecast, it is essential to understand the industry expansion and its key drivers. The current Cell-free DNA Mutation Diagnostics market size is approximately $1.4 billion, with a projected growth forecast of 14.1% Compound Annual Growth Rate (CAGR) from 2026 to 2033. The market is shaped by key forces such as technology shifts, including advancements in next-generation sequencing, regulations, such as those related to genetic testing, and consumer behavior, with increasing demand for non-invasive diagnostic tests.

Loading chart…

The largest region in the Cell-free DNA Mutation Diagnostics market is North America, driven by the presence of major market players and a well-established healthcare infrastructure. The fastest-growing region is expected to be Asia-Pacific, driven by increasing awareness and adoption of genetic testing. The market is highly competitive, with key players such as Illumina, Roche, and Thermo Fisher Scientific. As the market continues to evolve, it is essential for companies to stay ahead of the curve by investing in research and development, expanding their product portfolios, and forming strategic partnerships to drive industry expansion and capture a significant share of the Cell-free DNA Mutation Diagnostics market size.

Report Overview

Report Attribute	Details
Market size value in 2025	8.13 billion
Revenue forecast in 2033	14.18 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Natera; Guardant Health; Freenome Holdings; GRAIL; Exact Sciences Corporation; Foundation Medicine; Biocept; Thermo Fisher Scientific; Roche Diagnostics; Agilent Technologies; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; Myriad Genetics; BillionToOne
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell-free DNA Mutation Diagnostics market is poised for significant growth, driven by factors such as the increasing prevalence of cancer and the rising demand for non-invasive diagnostic tests. The global Cell-free DNA Mutation Diagnostics market size is expected to expand at a considerable growth forecast, driven by technological advancements and regulatory approvals.

Growth Drivers2 items

Advances in next-generation sequencing technologies have improved the sensitivity and specificity of Cell-free DNA Mutation Diagnostics, enabling the detection of rare mutations and driving market growth. This has led to increased adoption of these tests in clinical settings, contributing to the growth of the Cell-free DNA Mutation Diagnostics market size.

The growing demand for liquid biopsies has created new opportunities for Cell-free DNA Mutation Diagnostics, as these tests can provide valuable insights into cancer biology and treatment response, further driving the growth forecast of the Cell-free DNA Mutation Diagnostics market.

Restraints2 items

High cost of testing remains a significant barrier to the adoption of Cell-free DNA Mutation Diagnostics, particularly in low-resource settings, limiting the growth of the Cell-free DNA Mutation Diagnostics market size and constraining its growth forecast.

The lack of standardization in Cell-free DNA Mutation Diagnostics has hindered the development of consistent testing protocols, creating challenges for regulatory approval and reimbursement, which can impact the Cell-free DNA Mutation Diagnostics market.

Opportunities2 items

The integration of artificial intelligence and machine learning algorithms has the potential to enhance the accuracy and efficiency of Cell-free DNA Mutation Diagnostics, creating new opportunities for market growth and expansion of the Cell-free DNA Mutation Diagnostics market size.

The increasing demand for personalized medicine has created a growing need for Cell-free DNA Mutation Diagnostics, as these tests can provide valuable insights into individualized treatment strategies, driving the growth forecast of the Cell-free DNA Mutation Diagnostics market.

Challenges2 items

The complexity of data interpretation remains a significant challenge in Cell-free DNA Mutation Diagnostics, requiring specialized expertise and bioinformatic tools to accurately analyze and interpret test results, which can impact the growth of the Cell-free DNA Mutation Diagnostics market.

The need for regulatory frameworks that support the development and commercialization of Cell-free DNA Mutation Diagnostics is essential to ensure the long-term growth and sustainability of the Cell-free DNA Mutation Diagnostics market, as well as its growth forecast.

Market Segmentation

Loading chart…

The Application segment of the Cell-free DNA Mutation Diagnostics market is a crucial aspect of market taxonomy, as it determines the various uses of cell-free DNA mutation diagnostics. This segment can be further divided into subtypes, including prenatal testing, oncology testing, and transplant diagnostics. Each of these subtypes contributes to the overall Cell-free DNA Mutation Diagnostics market size, with prenatal testing being the largest contributor due to the increasing demand for non-invasive prenatal testing. The Cell-free DNA Mutation Diagnostics segmentation by application provides valuable insights into the market's growth prospects and trends.

The Types segment of the Cell-free DNA Mutation Diagnostics market refers to the different types of cell-free DNA mutation diagnostics tests available. This segment includes subtypes such as next-generation sequencing, polymerase chain reaction, and droplet digital polymerase chain reaction. Each of these subtypes has its own strengths and weaknesses, and their adoption rates vary depending on factors such as cost, sensitivity, and specificity. Understanding the Cell-free DNA Mutation Diagnostics market taxonomy is essential to analyzing the market's competitive landscape and identifying opportunities for growth. The types segment is a critical component of the overall market, as it drives innovation and adoption of cell-free DNA mutation diagnostics tests.

Cell-free DNA Mutation Diagnostics Segmentation Breakdown9 items

Application

Hoispital

Clinic

Laboratories

Others

Types

Kits

Instruments

Services

Regional Insights

Loading chart…

The Cell-free DNA Mutation Diagnostics market growth is poised to witness significant regional variations, with North America emerging as the largest region, accounting for approximately 40% of the global market. The Asia Pacific region, on the other hand, is expected to be the fastest-growing region, driven by increasing adoption of advanced diagnostic technologies, favorable policies, and substantial investments in healthcare infrastructure.

Key drivers for each region include: for North America, strong ecosystem maturity, high demographics awareness, and established infrastructure; for Europe, increasing adoption of non-invasive diagnostic techniques, supportive policies, and growing investments in research and development; for Asia Pacific, rising demographics demand, improving infrastructure, and expanding ecosystem maturity; for Latin America, growing adoption of advanced diagnostic technologies, increasing investments in healthcare, and favorable policies; and for Middle East & Africa, rising demographics demand, improving infrastructure, and increasing adoption of non-invasive diagnostic techniques.

The regional forecast suggests that the Cell-free DNA Mutation Diagnostics market will continue to grow, driven by increasing demand for non-invasive diagnostic technologies, favorable policies, and substantial investments in healthcare infrastructure. As the market continues to evolve, it is essential to monitor regional trends and market growth to identify opportunities and challenges.

Competitive Landscape

The Cell-free DNA Mutation Diagnostics market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on various fronts. The Cell-free DNA Mutation Diagnostics competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional strengths and niche offerings.

Companies in this space employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and commoditization. Key players are focusing on strategic initiatives to stay ahead in the market, as outlined below:

Illumina: innovation pipeline

Natera: premium pricing

Guardant Health: vertical integration

Freenome Holdings: local manufacturing

GRAIL: OEM tie-ups

Exact Sciences Corporation: regional expansion

Key Cell-free DNA Mutation Diagnostics Companies15 items

Illumina

Natera

Guardant Health

Freenome Holdings

GRAIL

Exact Sciences Corporation

Foundation Medicine

Biocept

Thermo Fisher Scientific

Roche Diagnostics

Agilent Technologies

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

Myriad Genetics

BillionToOne

Market Ecosystem

The Cell-free DNA Mutation Diagnostics ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream activities. This ecosystem is characterized by the interplay between technology providers, suppliers, integrators, channels, and end users, where value is created and captured through the development, integration, and delivery of cell-free DNA mutation diagnostics solutions. A thorough value chain analysis is necessary to understand the intricacies of this ecosystem.

Raw material/component suppliers — providing reagents and assays

Technology providers — developing diagnostic platforms and software

OEMs / manufacturers — producing diagnostic equipment and instruments

System integrators / EPCs — integrating systems and providing installation services

Distributors / channel partners — delivering products to end users

Service providers / after-sales — offering maintenance and support services

Regulators/standards bodies — establishing guidelines and approvals

The flow of value in the Cell-free DNA Mutation Diagnostics ecosystem is influenced by various control points, including regulatory approvals, technology advancements, and partnerships between participants. Dependency risks, such as input constraints and standards, can impact the adoption of cell-free DNA mutation diagnostics solutions. Furthermore, switching costs, partnerships, and interoperability requirements can affect the relationships between ecosystem participants, leading to varying degrees of collaboration and competition. The ecosystem's dynamics can differ by region, with diverse areas having distinct regulatory frameworks, market demands, and competitive landscapes.

Recent Industry Insights

The Cell-free DNA Mutation Diagnostics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Illumina and Merck, have focused on advancing liquid biopsy technologies for cancer diagnosis. Mergers and acquisitions, including the acquisition of Thrive Earlier Detection by Exact Sciences, have also been notable.

Furthermore, there have been several product launches and regulatory approvals in the Cell-free DNA Mutation Diagnostics market. For instance, the launch of Guardant Health's Shield test for colorectal cancer screening has expanded the market's offerings. Additionally, funding rounds, such as the $50 million series B financing of Foresight Diagnostics, have supported the growth of innovative startups in this space, driving the evolution of Cell-free DNA Mutation Diagnostics industry trends.

Analyst Overview

As the Lead Analyst for this study, I conclude that the Cell-free DNA Mutation Diagnostics market outlook is highly attractive, driven by the increasing demand for non-invasive diagnostic tests. The competitive intensity is moderate, with key players focusing on innovation and partnerships to stay ahead. The long-term outlook is promising, with the market expected to grow significantly over the next five years. The innovation landscape is rapidly evolving, with advancements in sequencing technologies and data analytics. However, the demand–supply balance may be affected by key risk factors, such as regulatory challenges and reimbursement issues.

11 items

1. Executive Summary

2. Cell-free DNA Mutation Diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell-free DNA Mutation Diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell-free DNA Mutation Diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hoispital

6.1.2. Clinic

6.1.3. Laboratories

6.1.4. Others

6.2. Global Cell-free DNA Mutation Diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Kits

6.2.2. Instruments

6.2.3. Services

6.3. Global Cell-free DNA Mutation Diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell-free DNA Mutation Diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell-free DNA Mutation Diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell-free DNA Mutation Diagnostics Market Competition by Key Manufacturers

8.1. Global Cell-free DNA Mutation Diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell-free DNA Mutation Diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Illumina

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Natera

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Guardant Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Freenome Holdings

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GRAIL

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Exact Sciences Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Foundation Medicine

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biocept

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche Diagnostics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Agilent Technologies

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Quest Diagnostics Incorporated

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Laboratory Corporation of America Holdings

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Myriad Genetics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. BillionToOne

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell-free DNA Mutation Diagnostics Market

Figure 4: Global Cell-free DNA Mutation Diagnostics Market: Drivers

Figure 5: Global Cell-free DNA Mutation Diagnostics Market: Challenges

Figure 6: Global Cell-free DNA Mutation Diagnostics Market: Trends

Figure 7: Global Cell-free DNA Mutation Diagnostics Market: Opportunity

Figure 8: Global Cell-free DNA Mutation Diagnostics Market: Restraint

Figure 9: Global Cell-free DNA Mutation Diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell-free DNA Mutation Diagnostics Market Value (USD Million) By Region

Figure 15: Global Cell-free DNA Mutation Diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell-free DNA Mutation Diagnostics Market Value (USD Million) By Region

Figure 23: Global Cell-free DNA Mutation Diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell-free DNA Mutation Diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell-free DNA Mutation Diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell-free DNA Mutation Diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell-free DNA Mutation Diagnostics Market Value (USD Million) By Region

Table 10: Global Cell-free DNA Mutation Diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell-free DNA Mutation Diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell-free DNA Mutation Diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell-free DNA Mutation Diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Illumina Basic Information And Sales Area

Table 31: Illumina. Products Portfolio

Table 32: Natera Basic Information And Sales Area

Table 33: Natera. Products Portfolio

Table 34: Guardant Health Basic Information And Sales Area

Table 35: Guardant Health. Products Portfolio

Table 36: Freenome Holdings Basic Information And Sales Area

Table 37: Freenome Holdings. Products Portfolio

Table 38: GRAIL Basic Information And Sales Area

Table 39: GRAIL. Products Portfolio

Table 40: Exact Sciences Corporation Basic Information And Sales Area

Table 41: Exact Sciences Corporation. Products Portfolio

Table 42: Foundation Medicine Basic Information And Sales Area

Table 43: Foundation Medicine. Products Portfolio

Table 44: Biocept Basic Information And Sales Area

Table 45: Biocept. Products Portfolio

Table 46: Thermo Fisher Scientific Basic Information And Sales Area

Table 47: Thermo Fisher Scientific. Products Portfolio

Table 48: Roche Diagnostics Basic Information And Sales Area

Table 49: Roche Diagnostics. Products Portfolio

Table 50: Agilent Technologies Basic Information And Sales Area

Table 51: Agilent Technologies. Products Portfolio

Table 52: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 53: Quest Diagnostics Incorporated. Products Portfolio

Table 54: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 55: Laboratory Corporation of America Holdings. Products Portfolio

Table 56: Myriad Genetics Basic Information And Sales Area

Table 57: Myriad Genetics. Products Portfolio

Table 58: BillionToOne Basic Information And Sales Area

Table 59: BillionToOne. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Cell-free DNA Mutation Diagnostics Market Value (USD Million) By Region

Table 65: Global Cell-free DNA Mutation Diagnostics Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cell-free DNA Mutation Diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.13 billion
Revenue forecast in 2033	14.18 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Natera; Guardant Health; Freenome Holdings; GRAIL; Exact Sciences Corporation; Foundation Medicine; Biocept; Thermo Fisher Scientific; Roche Diagnostics; Agilent Technologies; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; Myriad Genetics; BillionToOne
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Cell-free DNA Mutation Diagnostics Segmentation Breakdown9 items

Application

Hoispital

Clinic

Laboratories

Others

Types

Kits

Instruments

Services

Regional Insights

Loading chart…

Competitive Landscape

Illumina: innovation pipeline

Natera: premium pricing

Guardant Health: vertical integration

Freenome Holdings: local manufacturing

GRAIL: OEM tie-ups

Exact Sciences Corporation: regional expansion

Key Cell-free DNA Mutation Diagnostics Companies15 items

Illumina

Natera

Guardant Health

Freenome Holdings

GRAIL

Exact Sciences Corporation

Foundation Medicine

Biocept

Thermo Fisher Scientific

Roche Diagnostics

Agilent Technologies

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

Myriad Genetics

BillionToOne

Market Ecosystem

Raw material/component suppliers — providing reagents and assays

Technology providers — developing diagnostic platforms and software

OEMs / manufacturers — producing diagnostic equipment and instruments

System integrators / EPCs — integrating systems and providing installation services

Distributors / channel partners — delivering products to end users

Service providers / after-sales — offering maintenance and support services

Regulators/standards bodies — establishing guidelines and approvals

Recent Industry Insights

Analyst Overview

Table of Contents